Karyopharm Builds a Foundation for Advanced Analytics and AI

Artificial intelligence (AI) is clearly a priority in life science. A vast majority (90%) of industry executives say it will be important in driving commercial innovation and “74% believe AI will completely transform or significantly impact life sciences.”

Innovative companies like Karyopharm are ahead of the curve, going to market with a data foundation optimized for AI. I recently had a chance to speak with IT Director Jason Magyar about Karyopharm’s strategies for storing and managing data in an organized way using industry-standard data connectors.

Check out some of his recommendations for how emerging specialty pharma companies can efficiently commercialize their first products and simultaneously build a data foundation for the future.

You can read the entire interview with Jason here.